New hope for GVHD patients who failed first drug

NCT ID NCT02891395

First seen Jan 06, 2026 · Last updated May 14, 2026 · Updated 26 times

Summary

This study tested a drug called nilotinib in 65 adults with chronic graft-versus-host disease (GVHD), a complication after a stem cell transplant where donor cells attack the patient's body. Participants had already tried imatinib without success. The goal was to see if nilotinib could control the disease by measuring response after 3 months. The study was completed and aimed to offer a treatment option for those who did not respond to standard therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHU Besançon

    Besançon, France

  • CHU Bordeaux

    Bordeaux, France

  • CHU Clémenceau

    Caen, France

  • CHU Grenoble

    Grenoble, France

  • CHU Hotel Dieu

    Nantes, France

  • CHU Purpan

    Toulouse, France

  • CHU Sart Tilman

    Liège, Belgium

  • CHU d'Amiens

    Amiens, France

  • CHU d'Angers

    Angers, France

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France

  • CHU de Lyon

    Lyon, France

  • CHU de Nice

    Nice, France

  • CHU de STRASBOURG

    Strasbourg, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre hospitalier et régional de Lille

    Lille, France

  • Diseases of Blood Service HURIEZ hospital CHRU de LILLE

    Lille, 59037, France

  • HIA de Percy

    Clamart, France

  • Hopital Morvan

    Brest, France

  • Hopital NECKER

    Paris, France

  • Hôpital Saint Eloi

    Montpellier, France

  • Hôpital pitié Salpetrière

    Paris, France

  • Institut Paoli Calmettes

    Marseille, France

Conditions

Explore the condition pages connected to this study.